Cancer research

Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics

Retrieved on: 
Monday, September 19, 2022

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical data from BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, was published in Molecular Cancer Therapeutics.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical data from BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, was published in Molecular Cancer Therapeutics.
  • The article, titled BT8009: a Nectin-4 targeting Bicycle Toxin Conjugate for treatment of solid tumors is available online via this link .
  • The data published in Molecular Cancer Therapeutics describe BT8009s pre-clinical efficacy in a wide range of cell-derived xenograft and patient-derived xenograft tumor models, with full tumor regression frequently seen in large and small tumors.
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.

Hummingbird Bioscience Announces Trial in Progress Poster Presentation at the European Society for Medical Oncology Congress 2022

Retrieved on: 
Thursday, September 8, 2022

Hummingbird Bioscience management will attend ESMO 2022, which takes place in Paris from 9-13 September 2022.

Key Points: 
  • Hummingbird Bioscience management will attend ESMO 2022, which takes place in Paris from 9-13 September 2022.
  • The trial began enrolling in October 2021 and is ongoing in the UK.
  • The trial in progress poster will summarize the Phase 1 clinical trial design for HMBD-001 ( NCT05057013 ).
  • Hummingbird Bioscience is a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases.

Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors

Retrieved on: 
Wednesday, September 7, 2022

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced Phase I dose escalation top-line results from its Phase I/II trial of BT5528, a BTC targeting EphA2, in patients with advanced solid tumors.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced Phase I dose escalation top-line results from its Phase I/II trial of BT5528, a BTC targeting EphA2, in patients with advanced solid tumors.
  • The therapeutic profile from the dose escalation portion of the Phase I/II trial of BT5528 in patients with late-line disease suggests both differentiated safety and promising activity, most notably in ovarian and urothelial cancers, said Dominic Smethurst, Chief Medical Officer of Bicycle Therapeutics.
  • BT5528, a BTC targeting EphA2, a target for which prior antibody-based approaches have been unsuccessful, has demonstrated anti-tumor activity and differentiated tolerability.
  • Bicycle has established an RP2D dose (6.5mg/m2 every other week) and is enrolling ongoing expansion cohorts.

Inivata and Collaborators to Present New Data to Support the Application of RaDaR™ MRD Assay Across Tumor Types at ESMO Congress 2022

Retrieved on: 
Wednesday, September 7, 2022

Research Triangle Park, NC, USA and Cambridge, UK, 7 September 2022 -- Inivata, a leader in liquid biopsy, alongside collaborators, will present new data on its RaDaR™ assay for the detection of minimal residual disease (MRD) and recurrence at the European Society for Medical Oncology (ESMO) Congress, taking place on 9-13 September 2022. Inivata and NeoGenomics, Inivata’s parent company, will host a joint booth in the exhibition hall at the conference.

Key Points: 
  • Inivata and NeoGenomics, Inivatas parent company, will host a joint booth in the exhibition hall at the conference.
  • Inivata and collaborators will also present updated follow-up data and biomarker analysis from a study investigating administration of pre-operative ipilimumab and nivolumab for the treatment of advanced urothelial cancer.
  • We believe that the assay has the potential to transform cancer care as we progress towards broad-scale commercialization.
  • Inivata is partnering with pharmaceutical, biotechnology companies and commercial entities in early through late-stage cancer development programs across a range of cancer types.

Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, September 6, 2022

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13th, 2022 at 10:00 a.m.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13th, 2022 at 10:00 a.m.
  • A live webcast of the fireside chat will be accessible in the Investors and Media section of Bicycles Website at www.bicycletherapeutics.com .
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.
  • Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.

IEEE Open Journal of Engineering in Medicine and Biology Report Details Promise of New 3D Screening Tool for Accelerating Leading-edge Cancer Immunotherapies

Retrieved on: 
Thursday, August 25, 2022

Researchers at the University of Glasgow and the Cancer Research UK Beatson Institute in Glasgow also contributed to the study.

Key Points: 
  • Researchers at the University of Glasgow and the Cancer Research UK Beatson Institute in Glasgow also contributed to the study.
  • We look forward to seeing its life-saving impact in preclinical drug testing and, ultimately, precision medicine in the clinic.
  • The IEEE Engineering in Medicine and Biology Society (EMBS) is the world's largest international society of Biomedical Engineers.
  • The IEEE Open Journal of Engineering in Medicine and Biology covers the development and application of engineering concepts and methods to biology, medicine and health sciences to provide effective solutions to biological, medical and healthcare problems.

DynamiCure Announces IND Clearance to Advance First Antibody Candidate from its DC-6001 Anti-CD93 Program into Clinical Development

Retrieved on: 
Monday, August 22, 2022

The study is designed to evaluate the safety and efficacy of DCBY02 in adult patients with a wide range of advanced cancers.

Key Points: 
  • The study is designed to evaluate the safety and efficacy of DCBY02 in adult patients with a wide range of advanced cancers.
  • DynamiCure plans to submit the IND for the second monoclonal antibody from the DC-6001 program, DCSZ11, in the fourth quarter of 2022.
  • I look forward to continuing to collaborate with the DynamiCure team as they work to advance this and additional internal programs.
  • DynamiCure is employing a platform-agnostic approach to discover and develop therapeutics designed to address significant unmet medical needs in oncology and autoimmune disease.

Point-of-Donation Platform, Give A Little reaches £10m in donations

Retrieved on: 
Monday, August 8, 2022

LONDON, Aug. 8, 2022 /PRNewswire/ -- Give A Little today celebrates reaching £10m in donation revenues. This is a significant milestone that reflects over 4,000 charities who have made the move to cashless fundraising with the platform, taking payment card donations via contactless, Chip+PIN and online donations.

Key Points: 
  • The Give A Little platform provides the point-of-donation experience for donors and campaign management for charities to set up their fundraising.
  • All charities now need technology for handling cashless donations as donors have largely moved away from cash.
  • Give A Little Co-Founder, Ben Stewart, says: "The Give A Little team is incredibly proud to reach this 10m milestone.
  • Our specialisation around the point-of-donation experience leads to industry leading average donation values (over 10 for App donations and 40 for Web donations).

Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 4, 2022

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the second quarter ended June 30, 2022 and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the second quarter ended June 30, 2022 and provided recent corporate updates.
  • In June 2022, Bicycle announced that the first patient was dosed in the expansion cohorts of the Phase I/II study of BT5528, Bicycles second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2.
  • Bicycle intends to provide completed results of the dose escalation portion of the clinical trial during the third quarter of 2022.
  • In April 2022, Bicycle announced interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC targeting Nectin-4.

Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides

Retrieved on: 
Tuesday, August 2, 2022

The article, titled Gold-Mediated Multiple Cysteine Arylation for the Construction of Highly Constrained Bicycle Peptides is available at the publications section of the Bicycle website at this link .

Key Points: 
  • The article, titled Gold-Mediated Multiple Cysteine Arylation for the Construction of Highly Constrained Bicycle Peptides is available at the publications section of the Bicycle website at this link .
  • Assessment of the suitability of this methodology to Bicycle phage screening is underway, said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.
  • Bicycles are formed through the reaction of three cysteine residues within a linear sequence with a trivalent, symmetrical small molecule scaffold.
  • Bicycles with high binding affinities to therapeutically important targets are discovered using a proprietary phage display technology.